Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwME[xJO69VQ>? NIe5Z2FUSU6JRWK=
ALL-PO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrRTWM2OD1yLkC2N|U2KM7:TR?= MXvTRW5ITVJ?
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEm5O|Yh|ryP MUjTRW5ITVJ?
NCI-H748 NVK3[pJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\YUGlEPTB;MD6xNFM{PCEQvF2= NIPqfZhUSU6JRWK=
NKM-1 M1z4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMUC5NVIh|ryP NXr6TINzW0GQR1XS
ES1 M3rUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\wRWx{UUN3ME2wMlEyOjV3IN88US=> MWnTRW5ITVJ?
NCI-H1963 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XxZmlEPTB;MD6xNVU4QSEQvF2= NXvIdoJDW0GQR1XS
NCI-H1417 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXDVm9KSzVyPUCuNVI6PzRizszN M3vod3NCVkeHUh?=
NEC8 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMUO1Nlch|ryP MkHYV2FPT0WU
CRO-AP2 NX\Y[nhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TpfGlEPTB;MD6xOlg5QSEQvF2= MVTTRW5ITVJ?
A3-KAW NXHrXJlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX2TWM2OD1yLkG3OlI4KM7:TR?= MXXTRW5ITVJ?
SF539 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LoN2lEPTB;MD6xPVU6OyEQvF2= NImze|FUSU6JRWK=
NOS-1 M1PJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;aXGlEPTB;MD6xPVYyQSEQvF2= MnzTV2FPT0WU
NTERA-S-cl-D1 MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjTPGs6UUN3ME2wMlIxOTF|IN88US=> NXfPcGJHW0GQR1XS
COR-L88 NXLQU3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMkK5OVkh|ryP NU\qNllRW0GQR1XS
EM-2 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjiXJlKSzVyPUCuNlQxPzlizszN NFjtW2xUSU6JRWK=
KARPAS-45 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLPTWM2OD1yLkK3PFM{KM7:TR?= MnfOV2FPT0WU
DSH1 M3[2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\5UI9KSzVyPUCuNlg4ODhizszN MorzV2FPT0WU
HT-144 NYDlXng1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;0TWM2OD1yLkOwNlU3KM7:TR?= MVrTRW5ITVJ?
ATN-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zrcGlEPTB;MD6zNFU4PiEQvF2= MVjTRW5ITVJ?
HEL NXqzS5E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwM{GzOFgh|ryP M3[yTnNCVkeHUh?=
NB12 M{HPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwM{G3OVYh|ryP NYLJOI9yW0GQR1XS
LU-139 NGPYc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjRc5NKSzVyPUCuN|M2OSEQvF2= MYrTRW5ITVJ?
J-RT3-T3-5 M{TFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XzeWlEPTB;MD6zN|cyPiEQvF2= NGe1fmlUSU6JRWK=
MOLT-13 NI\VXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwM{O4NUDPxE1? NI\3fYVUSU6JRWK=
SR MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnVd2FnUUN3ME2wMlM1OjZzIN88US=> NUW5OHBwW0GQR1XS
CMK M1H2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL5TWM2OD1yLkO1O|I4KM7:TR?= MXvTRW5ITVJ?
ES8 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH5TWM2OD1yLkO2NFIzKM7:TR?= MlflV2FPT0WU
LB647-SCLC NYDaOo12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwM{[3N{DPxE1? NXnySFdOW0GQR1XS
TE-8 NX73VlE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwM{[5N|Uh|ryP M1PLcnNCVkeHUh?=
BV-173 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6xe2pKSzVyPUCuN|cyOjFizszN MY\TRW5ITVJ?
DEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwM{e0PFch|ryP NF7ENoJUSU6JRWK=
ARH-77 NGj3UpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHyTWM2OD1yLkO4NVk{KM7:TR?= NYTIdIlVW0GQR1XS
NCCIT MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKzWYZKSzVyPUCuN|g3PDlizszN NVTpUoZVW0GQR1XS
RPMI-8402 NITHWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwM{i3NFEh|ryP NXr2ToN[W0GQR1XS
MONO-MAC-6 M2jTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWyZnJKSzVyPUCuN|g4PzZizszN MULTRW5ITVJ?
SK-MM-2 M3;y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT0TWM2OD1yLkO5PFY5KM7:TR?= NFrB[3JUSU6JRWK=
CHP-126 MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvNUI9KSzVyPUCuOFAzOzFizszN NXzWV5U6W0GQR1XS
A101D M2S3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T0OmlEPTB;MD60NFMh|ryP MkX6V2FPT0WU
SCH NVXKdJVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf3XIpkUUN3ME2wMlQxOzR{IN88US=> Mom0V2FPT0WU
NMC-G1 NFXS[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwNECzOlch|ryP NIHhe4tUSU6JRWK=
NCI-H209 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzXTWM2OD1yLkSwOlE{KM7:TR?= NHvMOpFUSU6JRWK=
MOLT-16 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X0fmlEPTB;MD60NVAyPyEQvF2= NUP2OFRQW0GQR1XS
RPMI-6666 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;KTWM2OD1yLkSxNVIh|ryP Mo[0V2FPT0WU
OPM-2 M4H3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfYfohKSzVyPUCuOFE2OTNizszN NX7Rd5lbW0GQR1XS
MRK-nu-1 NFvzUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNEOxOVMh|ryP NFLkWnpUSU6JRWK=
BC-1 NUTuXWx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwNEO0NFMh|ryP MlzHV2FPT0WU
MHH-NB-11 NWTuTZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[0TWM2OD1yLkSzOFU{KM7:TR?= MlvpV2FPT0WU
Ramos-2G6-4C10 NGfLRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;FUVJKSzVyPUCuOFM5QTdizszN NGPjbmlUSU6JRWK=
LS-513 NFjSR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;6Z2lEPTB;MD60OFUxOSEQvF2= NFjrOYJUSU6JRWK=
K5 NFewO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnmTWM2OD1yLkS3NFI2KM7:TR?= MlnGV2FPT0WU
HOP-62 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv5epd7UUN3ME2wMlQ5OzV6IN88US=> MVvTRW5ITVJ?
NCI-H187 NGDP[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrkTWM2OD1yLkS5NlI4KM7:TR?= MoXRV2FPT0WU
BE-13 M3rZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmwNZhKSzVyPUCuOFk3PjFizszN NVHwb|B{W0GQR1XS
HC-1 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\YWGlEPTB;MD61NFQ4OyEQvF2= NUDTUZZqW0GQR1XS
ACN NGG4OYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WwWmlEPTB;MD61NVAzQCEQvF2= MWnTRW5ITVJ?
HCC1599 NXvPOFlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwNUG1O{DPxE1? NGS2XHBUSU6JRWK=
MV-4-11 NGXl[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fnbWlEPTB;MD61N|A1OSEQvF2= MkToV2FPT0WU
LC-2-ad NWC5WWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwNUO2OlMh|ryP MXPTRW5ITVJ?
HL-60 NUfuNm9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwNUSyOlEh|ryP M{LoR3NCVkeHUh?=
NB17 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf2TWM2OD1yLkW0N|gh|ryP M13HWHNCVkeHUh?=
TE-1 NX\UdlRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PFNWlEPTB;MD61OVMxPiEQvF2= M3rLcXNCVkeHUh?=
NCI-H524 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjYVHlKSzVyPUCuOVU1ODFizszN M4fRe3NCVkeHUh?=
MZ7-mel MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwNU[xNFUh|ryP NHvPR4RUSU6JRWK=
L-363 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XmbmlEPTB;MD61OlY2PyEQvF2= M{L5XnNCVkeHUh?=
BL-41 NVG4VFE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rEZ2lEPTB;MD61Olg5QSEQvF2= MVnTRW5ITVJ?
LU-134-A NXrkT5NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDjfVdnUUN3ME2wMlU4ODd|IN88US=> NYPtdHJqW0GQR1XS
SIG-M5 NI\lc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHMTWM2OD1yLkW3PFQ5KM7:TR?= MX\TRW5ITVJ?
ONS-76 NGS3bZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnlPZhKSzVyPUCuOVgzPDJizszN MmrYV2FPT0WU
KARPAS-299 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1cHNKSzVyPUCuOVg2ODRizszN NUnwelI3W0GQR1XS
DU-4475 M2TDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW0TWM2OD1yLkW4O|A{KM7:TR?= NXXLPHJ6W0GQR1XS
NB69 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTFfphKSzVyPUCuOVk5OjVizszN M{D1VXNCVkeHUh?=
MHH-PREB-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNkC3NVkh|ryP MULTRW5ITVJ?
LU-165 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPITWM2OD1yLk[xPFEzKM7:TR?= MknsV2FPT0WU
LOUCY M4fGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwNkOzOlQh|ryP M2m3d3NCVkeHUh?=
NCI-H526 M3XpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwNkO1OFEh|ryP Mm\LV2FPT0WU
KE-37 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfadGZKSzVyPUCuOlQzPzZizszN MULTRW5ITVJ?
NALM-6 NWnvd|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu5NHZKSzVyPUCuOlQ5PiEQvF2= NVzQe455W0GQR1XS
CW-2 M2f3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT5TWM2OD1yLk[1O|k1KM7:TR?= NV;heY5WW0GQR1XS
SU-DHL-1 M33Lc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe3WYFPUUN3ME2wMlY2QTR5IN88US=> NEPOU5pUSU6JRWK=
NB13 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnETWM2OD1yLk[2PFE4KM7:TR?= NIH3UIFUSU6JRWK=
QIMR-WIL MonnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjwflhKUUN3ME2wMlY5OzR|IN88US=> MkTzV2FPT0WU
ECC12 NVPwfYFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDGT2NKSzVyPUCuO|AxQDZizszN M1rXOnNCVkeHUh?=
KALS-1 M1PZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwN{C0PVIh|ryP M3fySnNCVkeHUh?=
COR-L279 NX\5OpFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T6e2lEPTB;MD63NFk6PiEQvF2= NWfDSpVJW0GQR1XS
NB14 NU\WZlU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnCTWM2OD1yLkeyOlE4KM7:TR?= NIDPVpZUSU6JRWK=
CCRF-CEM NH;OUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwN{S2OlEh|ryP Mk\3V2FPT0WU
SW954 MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;DVGlEPTB;MD63OVk6QSEQvF2= MVTTRW5ITVJ?
IST-SL1 M2TMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnm[IdwUUN3ME2wMlc4OzR6IN88US=> NUH5[WxMW0GQR1XS
LAMA-84 NYnhenY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrmfnpKUUN3ME2wMlc4PTZ5IN88US=> MVrTRW5ITVJ?
Daudi MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOzbXlKSzVyPUCuO|c3QDFizszN M1X6fnNCVkeHUh?=
BC-3 M13LTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDOeJdKSzVyPUCuO|g{ODhizszN MmTYV2FPT0WU
HCC2998 NYCxepN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwN{izOkDPxE1? NXfoR4ZyW0GQR1XS
NCI-H69 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWruPG1XUUN3ME2wMlgxOTR5IN88US=> NVPhVYs5W0GQR1XS
CPC-N NXi1PIZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TzdGlEPTB;MD64NFUzPCEQvF2= MkTEV2FPT0WU
NOMO-1 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjwXo1KSzVyPUCuPFExQDRizszN Mn\5V2FPT0WU
CESS MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m3cGlEPTB;MD64NVE6PyEQvF2= MlnyV2FPT0WU
LC4-1 NUD3XHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXnTWM2OD1yLki0NFA4KM7:TR?= NVe3[4ViW0GQR1XS
BL-70 M13zRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fpcWlEPTB;MD64OVcxOiEQvF2= Ml[xV2FPT0WU
ES4 M1\0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r5XmlEPTB;MD64OVg3QCEQvF2= NHzB[phUSU6JRWK=
HCE-T MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr2[3ZLUUN3ME2wMlg4OTdzIN88US=> MWnTRW5ITVJ?
JAR NFnTRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnWTWM2OD1yLki3PFI4KM7:TR?= MXTTRW5ITVJ?
ST486 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjXUVVKSzVyPUCuPFc6OTdizszN MWjTRW5ITVJ?
KS-1 NIS4WVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3JbIptUUN3ME2wMlg5ODl4IN88US=> MYnTRW5ITVJ?
GDM-1 M4\6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX0S5JKSzVyPUCuPFg3QDdizszN M{LEU3NCVkeHUh?=
EHEB NYnubowzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITjcG5KSzVyPUCuPVI2QDVizszN M4n2VXNCVkeHUh?=
LB2518-MEL NX3jXIQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[xW4FmUUN3ME2wMlk{Ojh2IN88US=> MVLTRW5ITVJ?
GOTO NX7lb5kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwOUWwO|Yh|ryP M2CwdnNCVkeHUh?=
LXF-289 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwOUW5NFEh|ryP NHnHU2hUSU6JRWK=
ES6 M4f2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vRZmlEPTB;MD65OlQ{PyEQvF2= NF\1e4pUSU6JRWK=
OS-RC-2 M3XXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTaTWM2OD1yLkm2PFMh|ryP M4TpPHNCVkeHUh?=
DMS-153 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwOUe0Olkh|ryP MlPNV2FPT0WU
SK-PN-DW M{PaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfGS2QyUUN3ME2wMlk4QDNzIN88US=> MWfTRW5ITVJ?
HH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjue4x[UUN3ME2wMlk5QTV7IN88US=> MlGwV2FPT0WU
SH-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTFwMEK0NUDPxE1? NWHXS|FkW0GQR1XS
MOLT-4 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTFwMEO0OVQh|ryP NXHrTmN{W0GQR1XS
TGW Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\jTphKSzVyPUGuNFc3PzVizszN MXPTRW5ITVJ?
L-540 NHLxeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIC2dVJKSzVyPUGuNVA3ODRizszN M1vPXnNCVkeHUh?=
PF-382 NFHs[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFwMUG1NVMh|ryP NGfiT4NUSU6JRWK=
LC-1F MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\zTJNKSzVyPUGuNVIxODdizszN NXLlUFN[W0GQR1XS
OVCAR-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\FSmlEPTB;MT6xN|E3PSEQvF2= MVTTRW5ITVJ?
A4-Fuk NYq0W49uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwMUWzOlQh|ryP NUO2O4c2W0GQR1XS
HCC2218 NYnmeYFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHGZolKSzVyPUGuNVY3PDFizszN MoG5V2FPT0WU
HAL-01 NVvuS2tJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDuTWM2OD1zLkG2PVQ{KM7:TR?= M2nzUXNCVkeHUh?=
IST-MEL1 NGKyWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LISmlEPTB;MT6xO|Y2QSEQvF2= NXjMNnZRW0GQR1XS
NCI-H719 M336Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO4S2NKSzVyPUGuNVc5QThizszN M{OyWHNCVkeHUh?=
EVSA-T MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFwMUixNVQh|ryP MUfTRW5ITVJ?
SK-NEP-1 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwMkCyOlYh|ryP NV;4VGZnW0GQR1XS
OCUB-M NUXLfYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUiyS2tXUUN3ME2xMlIyPDh7IN88US=> M33PWHNCVkeHUh?=
MEG-01 NX3qbmNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[2Z2lEPTB;MT6yNlEyQCEQvF2= MVHTRW5ITVJ?
no-10 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPrTWM2OD1zLkKzNVEzKM7:TR?= MYfTRW5ITVJ?
MHH-CALL-2 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonPTWM2OD1zLkK0O|IyKM7:TR?= MmDKV2FPT0WU
SK-N-DZ MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rIXGlEPTB;MT6yOFc4PiEQvF2= NHPid2hUSU6JRWK=
SCLC-21H NHPlPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwMk[0O|gh|ryP MV3TRW5ITVJ?
CTV-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq2[mZiUUN3ME2xMlI4PDJ3IN88US=> M3j6R3NCVkeHUh?=
NB1 M3XsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nsTGlEPTB;MT6yO|c{OiEQvF2= M2jsbHNCVkeHUh?=
NCI-H64 NGL5OnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwMki0OlIh|ryP NGrHVlZUSU6JRWK=
MDA-MB-134-VI MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DRTGlEPTB;MT6yPFU4PyEQvF2= NHG1bFVUSU6JRWK=
LB2241-RCC MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL0WmFqUUN3ME2xMlI5PjZ|IN88US=> MmHwV2FPT0WU
8-MG-BA MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwMki4OlYh|ryP NH3VWHpUSU6JRWK=
LP-1 M1LPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[3V2lEPTB;MT6yPVk1PyEQvF2= MX;TRW5ITVJ?
LS-411N NHXQboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LqNGlEPTB;MT6zNFk6QCEQvF2= MVrTRW5ITVJ?
CAL-148 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnVd2JNUUN3ME2xMlMzPTR{IN88US=> Mk\LV2FPT0WU
NCI-H2171 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1H4cWlEPTB;MT6zOFUxOiEQvF2= NI\xTHdUSU6JRWK=
JiyoyeP-2003 M3S4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\uTWM2OD1zLkO1N|kh|ryP NUX6Wmd6W0GQR1XS
NCI-H2107 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmruTWM2OD1zLkO1PFg{KM7:TR?= M1rVT3NCVkeHUh?=
BB30-HNC NHLDVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwM{i5O|gh|ryP NITtSGJUSU6JRWK=
K-562 M1PENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFj0WYJKSzVyPUGuN|kzOTlizszN M4L2UHNCVkeHUh?=
PSN1 M12xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjiNWxKSzVyPUGuOFIzQDdizszN MkTGV2FPT0WU
HCC2157 M2TmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwNEK2PVEh|ryP MWnTRW5ITVJ?
SBC-1 NFP2XmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXpTWM2OD1zLkSyO|QyKM7:TR?= MWrTRW5ITVJ?
MC116 NVHFNm9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwNEO2NVUh|ryP NUm2cHNZW0GQR1XS
KARPAS-422 M1;nVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH5TWM2OD1zLkS1N|U5KM7:TR?= NH7XfmVUSU6JRWK=
LB996-RCC M4HNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXIUIRKSzVyPUGuOFcyODNizszN MYPTRW5ITVJ?
MSTO-211H NV3CTXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSxTWM2OD1zLkS3PVg4KM7:TR?= M3u2SHNCVkeHUh?=
BT-474 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwNUG3OlQh|ryP MUjTRW5ITVJ?
A388 NWPXUphxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3qTWM2OD1zLkWxPVQ2KM7:TR?= MlvhV2FPT0WU
SJSA-1 M{nZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jXbWlEPTB;MT61NlI3KM7:TR?= MkLGV2FPT0WU
COLO-829 NWP2WldjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[wVmlEPTB;MT61N|U3PCEQvF2= M2S2XHNCVkeHUh?=
KM-H2 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwNU[2O{DPxE1? Mn7MV2FPT0WU
GR-ST M336SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPYfpIyUUN3ME2xMlU3QDJizszN Mn3mV2FPT0WU
RPMI-8866 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q5[2lEPTB;MT62NFE1PCEQvF2= M1[yW3NCVkeHUh?=
KG-1 NIjNUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnofVFKSzVyPUGuOlE6ODFizszN NHT1SYhUSU6JRWK=
NCI-H82 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPVSYU2UUN3ME2xMlY{PDB4IN88US=> M1ThfnNCVkeHUh?=
LB1047-RCC NW[w[pNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DUOmlEPTB;MT62N|Q2QSEQvF2= MVXTRW5ITVJ?
KM12 M4SwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[4ZVMxUUN3ME2xMlY1PyEQvF2= MnTvV2FPT0WU
NB5 NWHxNGE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwNkW2O|ch|ryP NGXFWWRUSU6JRWK=
HDLM-2 NH3sTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLBTWM2OD1zLk[4NlgyKM7:TR?= MWXTRW5ITVJ?
KU812 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ZVYVKSzVyPUGuOlk3ODVizszN Ml\4V2FPT0WU
DB Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmwToxYUUN3ME2xMlcxOzV|IN88US=> NEHVN|NUSU6JRWK=
HD-MY-Z MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fKZWlEPTB;MT63OVI{PCEQvF2= Mn:xV2FPT0WU
KURAMOCHI NHXXV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLoTWM2OD1zLke3NlA4KM7:TR?= M3jmOXNCVkeHUh?=
ETK-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwN{i4O|kh|ryP NGrsfIRUSU6JRWK=
SK-UT-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG4c3dKSzVyPUGuO|k{QDhizszN M4TwNHNCVkeHUh?=
HUTU-80 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwN{m1NFgh|ryP M4TSUHNCVkeHUh?=
ES7 NYGxelMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LDNWlEPTB;MT64NFMxOiEQvF2= NVf5VYJ3W0GQR1XS
SW872 NH;Rc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwOEGzPVUh|ryP MUPTRW5ITVJ?
TK10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwOEOxNFgh|ryP NXTPb5ZHW0GQR1XS
LB831-BLC M2PRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDZd5pKSzVyPUGuPFM2PjNizszN Ml;4V2FPT0WU
TE-9 M3rwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfaTWM2OD1zLki0OFIzKM7:TR?= NVfnfIlKW0GQR1XS
MLMA MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;vc5FKSzVyPUGuPFgzOzRizszN MXPTRW5ITVJ?
D-542MG M2izW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknNTWM2OD1zLki5N|c{KM7:TR?= MYTTRW5ITVJ?
EW-16 M2jSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn63TWM2OD1zLkmyO|Ih|ryP NGrXZXpUSU6JRWK=
LOXIMVI MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTJXI12UUN3ME2xMlk{OjhizszN NGHmSGdUSU6JRWK=
GB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fFU2lEPTB;MT65N|g3PiEQvF2= NUnZN2FkW0GQR1XS
IST-SL2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{npdWlEPTB;Mj6wNFI3OiEQvF2= NWjueotqW0GQR1XS
LAN-6 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3jTWM2OD1{LkCxPVY3KM7:TR?= NUL5UXNZW0GQR1XS
NCI-H510A M1u1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPablBjUUN3ME2yMlA1PTB{IN88US=> NEjUWZBUSU6JRWK=
NCI-H1092 NEjsUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XIeGlEPTB;Mj6wOVEzPCEQvF2= MkWwV2FPT0WU
HT M4HxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwMUC0OVQh|ryP M1zVW3NCVkeHUh?=
RL95-2 NHjtbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwMUG0PFIh|ryP NF;vc5BUSU6JRWK=
NCI-H1355 NGntV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonYTWM2OD1{LkGxO|kzKM7:TR?= MoH1V2FPT0WU
NCI-H720 NWnYe|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;idWlEPTB;Mj6xOlg4OyEQvF2= MoXNV2FPT0WU
NCI-H1522 NVLDbYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELpXZZKSzVyPUKuNlE4OjNizszN MVvTRW5ITVJ?
LB373-MEL-D M{jUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M322PGlEPTB;Mj6yOlkxOiEQvF2= MnfkV2FPT0WU
DG-75 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP5PXRKSzVyPUKuNlcyPDhizszN MmrRV2FPT0WU
ML-2 NFjmeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M334VWlEPTB;Mj6zNlg2PSEQvF2= MULTRW5ITVJ?
SF126 M3:0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{frUGlEPTB;Mj6zN|A6PCEQvF2= MUjTRW5ITVJ?
MPP-89 NYHoUWVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom5TWM2OD1{LkOzNVQ2KM7:TR?= NGnYR4hUSU6JRWK=
NCI-H345 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJwM{OyO|ch|ryP NX\1TG44W0GQR1XS
LS-123 MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojWTWM2OD1{LkO0PVM3KM7:TR?= NYXOUXNFW0GQR1XS
NB10 MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jONmlEPTB;Mj60NVA6OiEQvF2= MVvTRW5ITVJ?
CGTH-W-1 M3HSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PtWGlEPTB;Mj60NlI3PyEQvF2= MlHGV2FPT0WU
CP66-MEL M1HZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHteJdKSzVyPUKuOFc4PyEQvF2= MkjjV2FPT0WU
L-428 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n6NGlEPTB;Mj60PFUzOSEQvF2= MXHTRW5ITVJ?
DMS-79 MlzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorqTWM2OD1{LkW0NVA{KM7:TR?= M3fW[nNCVkeHUh?=
NCI-H1882 NGHZNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJwNke1OlIh|ryP NGn1d2lUSU6JRWK=
KGN NIjmS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zh[GlEPTB;Mj63Olg4PiEQvF2= M{HDZnNCVkeHUh?=
EW-1 NGW0TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF60VItKSzVyPUKuO|cxQDNizszN MXTTRW5ITVJ?
U-266 NIDiTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO1TWM2OD1{Lki0PFI{KM7:TR?= Mln1V2FPT0WU
COLO-320-HSR M33Bemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwOEW2OFEh|ryP M3i2Z3NCVkeHUh?=
KMOE-2 MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml62TWM2OD1{Lki3O|EyKM7:TR?= M{LBOHNCVkeHUh?=
BB49-HNC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLNTWM2OD1{LkmyOFgh|ryP NXT0e5ZZW0GQR1XS
GI-1 M3u3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDsTWM2OD1{LkmyPVU4KM7:TR?= M3TPenNCVkeHUh?=
NCI-H1304 Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHiTWM2OD1|LkCwOVEyKM7:TR?= NIG1OW5USU6JRWK=
NCI-H2227 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe2b5ppUUN3ME2zMlAzODd7IN88US=> MXHTRW5ITVJ?
U-87-MG NGPpWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL0TWM2OD1|LkCzOVE{KM7:TR?= NIm2foJUSU6JRWK=
NCI-H747 M3[4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;PNnlKSzVyPUOuNFUzODZizszN MV;TRW5ITVJ?
CTB-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf2NXlDUUN3ME2zMlA2Ozd4IN88US=> NYPWZ2hvW0GQR1XS
RPMI-8226 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTNwMUSzO|gh|ryP M1PSfnNCVkeHUh?=
NCI-H2141 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm0TWM2OD1|LkG2OVY3KM7:TR?= NX3xNYRrW0GQR1XS
IST-MES1 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPxfnpKSzVyPUOuNVgzPzlizszN MknSV2FPT0WU
TE-5 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWOwUm9KUUN3ME2zMlIyOzR{IN88US=> M4PVZnNCVkeHUh?=
UACC-257 NVj4[ol1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[zbWpKSzVyPUOuOFM3PTlizszN NHKxVJhUSU6JRWK=
SK-N-FI M{Pid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPjTWM2OD1|LkS1NlI4KM7:TR?= NYPpVJpbW0GQR1XS
MFH-ino MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTNwNE[1PFkh|ryP M17OOXNCVkeHUh?=
SF268 NFS0XmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT6WIh1UUN3ME2zMlQ5OTd2IN88US=> M2TnWnNCVkeHUh?=
TE-12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF62b3dKSzVyPUOuOVE3QTlizszN M4jOSXNCVkeHUh?=
NB6 M37XXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrqdo1KSzVyPUOuOVU2PjNizszN NIHMV|JUSU6JRWK=
DJM-1 M{fqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:0SoQ5UUN3ME2zMlU6QDl7IN88US=> NFfZNItUSU6JRWK=
MZ1-PC NF;SZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\k[3NDUUN3ME2zMlYyPjJ2IN88US=> MXLTRW5ITVJ?
OCI-AML2 M4DCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LTSmlEPTB;Mz62NlY4OSEQvF2= MVfTRW5ITVJ?
NCI-H1155 NV63R|VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTNwN{C5OFch|ryP NWPoeYhxW0GQR1XS
RKO M3jpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH5WJR2UUN3ME2zMlc4OTh7IN88US=> M3u0XXNCVkeHUh?=
ECC4 M3fT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm5c2dKSzVyPUOuPVcyQTVizszN NET5eWhUSU6JRWK=
BB65-RCC M2GzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfnc29KSzVyPUOuPVc2PDdizszN NHjTd3ZUSU6JRWK=
EB-3 M3qyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnNSXBKSzVyPUOuPVk3OzNizszN Mn\iV2FPT0WU
SHP-77 NVnOTY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDBcGp[UUN3ME20MlAxPTJ2IN88US=> NEPL[5pUSU6JRWK=
NCI-H2196 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3qV4ppUUN3ME20MlA2PjJ3IN88US=> NY[1cGV2W0GQR1XS
GI-ME-N NELnSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXFTWM2OD12LkC2N|k6KM7:TR?= MnXBV2FPT0WU
MN-60 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXVOGdKSzVyPUSuNVA5PyEQvF2= NUf4OVB{W0GQR1XS
NCI-H1694 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jPSWlEPTB;ND6xN|QxPSEQvF2= NXKzeWM4W0GQR1XS
LU-65 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPoN4RJUUN3ME20MlE2OzN{IN88US=> MWXTRW5ITVJ?
NCI-H1436 NFjVcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPoPYF7UUN3ME20MlE5OzN|IN88US=> NIP1ZYdUSU6JRWK=
KINGS-1 MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjhcldlUUN3ME20MlMyPDN{IN88US=> M2DsdHNCVkeHUh?=
GT3TKB MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;nTWM2OD12LkOzNlY5KM7:TR?= NV3heZdGW0GQR1XS
Becker MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn6UGdNUUN3ME20MlM4OzF{IN88US=> MUfTRW5ITVJ?
HCC1187 NHvDNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XJXWlEPTB;ND64PVY2PyEQvF2= MYHTRW5ITVJ?
D-502MG NYDT[FV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwMEC0NVYh|ryP MoHqV2FPT0WU
VA-ES-BJ NYjCdpQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y3eWlEPTB;NT6xN|c4QCEQvF2= NEDYW3FUSU6JRWK=
NB7 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzyTWM2OD13LkG0NVEzKM7:TR?= MYLTRW5ITVJ?
SW962 M4D3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljMTWM2OD13LkO4PFE1KM7:TR?= M3TvUHNCVkeHUh?=
no-11 NVjlN4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlryTWM2OD13Lke2N|Q{KM7:TR?= NWnRdWtiW0GQR1XS
KNS-81-FD NIfHclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXXfoh1UUN3ME21MlkxPjl2IN88US=> MXPTRW5ITVJ?
COLO-684 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrHTVRoUUN3ME21Mlk6PDl2IN88US=> MlXKV2FPT0WU
D-263MG NHXhRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3T[HpKSzVyPU[uNFg5QTVizszN MoTtV2FPT0WU
EW-24 M1fHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnyUm9rUUN3ME22MlI5PTFizszN MnHhV2FPT0WU
TE-10 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTZwNEK2NlMh|ryP MY\TRW5ITVJ?
EKVX Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3aTWM2OD14LkS2N|IyKM7:TR?= NGfaNIdUSU6JRWK=
NCI-H1648 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjFUlZKSzVyPU[uOlc2PTdizszN NIHvUo9USU6JRWK=
LB771-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XmTmlEPTB;Nj65NlMxOSEQvF2= NXzwSGU3W0GQR1XS
SK-MEL-1 NWq4NG9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjLTWM2OD16LkGzNVY3KM7:TR?= MnHYV2FPT0WU
COLO-668 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfyTWM2OD16LkK3O|g3KM7:TR?= MXrTRW5ITVJ?
EW-12 M3rO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRThwNEC4NFMh|ryP MYLTRW5ITVJ?
A253 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLxTWM2OD16Lki0OlYyKM7:TR?= M1PsfHNCVkeHUh?=
NCI-H2126 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjHTGlEUUN3ME24Mlg6OzF7IN88US=> NF7tb3FUSU6JRWK=
Calu-6 NY\zS4kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;ae29KSzVyPUiuPVkxPDJizszN MkewV2FPT0WU
NCI-H23 NXTqU5lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfhV5pKSzVyPUmuNVc4PDZizszN MYrTRW5ITVJ?
WSU-NHL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyyNG5wUUN3ME25Mlc4PDd6IN88US=> Mn;MV2FPT0WU
MMAC-SF NHO5cYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTlwOUe5NFQh|ryP Mn7RV2FPT0WU
SK-LMS-1 NVP1elB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2O4fGlEPTB;MUCuNlg{PCEQvF2= M4HiV3NCVkeHUh?=
GCIY NXHZRpFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT4TWM2OD1zMD61PVI1KM7:TR?= NWHwUVNpW0GQR1XS
TE-15 M3e0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX3TWM2OD1zMT62NFA1KM7:TR?= M4SyT3NCVkeHUh?=
EoL-1-cell M13ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLkN|NiUUN3ME2xNU44Pjh{IN88US=> NEH1S|lUSU6JRWK=
NCI-H2081 M4XIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\5TWM2OD1zMT63O|g3KM7:TR?= M4n1fnNCVkeHUh?=
EW-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ITWM2OD1zMj6yOFY{KM7:TR?= MlriV2FPT0WU
CAS-1 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHUN3dKSzVyPUGyMlM3OzFizszN Mm\GV2FPT0WU
C2BBe1 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrMTJNLUUN3ME2xNk43OTNzIN88US=> NWrZUXVJW0GQR1XS
D-247MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF{Lke5OVIh|ryP NUSxVlVUW0GQR1XS
NCI-SNU-5 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF{LkiwNVMh|ryP M33KWHNCVkeHUh?=
LS-1034 NU\RdnNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfEbpVKSzVyPUG0MlM6PzVizszN MYHTRW5ITVJ?
EW-18 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzvO2tKSzVyPUG0MlQ1QCEQvF2= M{Kz[HNCVkeHUh?=
Raji MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILINllKSzVyPUG0MlUxPDlizszN M2\UXXNCVkeHUh?=
D-283MED MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rrUGlEPTB;MUSuOlI4OSEQvF2= M3vOSHNCVkeHUh?=
MZ2-MEL NWrze3MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq2fYhKSzVyPUG0Mlk3QTZizszN NFTKUmZUSU6JRWK=
NCI-SNU-16 MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXpbGpKSzVyPUG1MlQ3OzNizszN MYfTRW5ITVJ?
P30-OHK NH\TcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[0NWlEPTB;MUeuO|g{OSEQvF2= NGLjSGFUSU6JRWK=
RXF393 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n0RWlEPTB;MUmuNFE5PiEQvF2= NUPKTVZqW0GQR1XS
NCI-H1395 NWHvW3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTpc5dKSzVyPUKwMlY4ODNizszN M4LafXNCVkeHUh?=
U-698-M NFrXUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7UTWM2OD1{MD63NFc2KM7:TR?= M2L0c3NCVkeHUh?=
NCI-SNU-1 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfZfGw3UUN3ME2yNE44OjJ|IN88US=> M3TOVXNCVkeHUh?=
SW684 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLuTWM2OD1{MT6xO|E3KM7:TR?= MmXNV2FPT0WU
NCI-H716 NH\YcYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJzLkOxOVQh|ryP Mk[xV2FPT0WU
JVM-2 M{HiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PINmlEPTB;MkGuOFE{OyEQvF2= M1\SVHNCVkeHUh?=
NCI-H1581 NXTqbGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJ{LkSxOFgh|ryP M2Pzd3NCVkeHUh?=
CA46 NEXp[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor1TWM2OD1|MT62PVM3KM7:TR?= Ml7PV2FPT0WU
SNB75 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uze2lEPTB;M{OuOlUxOyEQvF2= NXvHOmk4W0GQR1XS
KNS-42 NHnTUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xl[mlEPTB;M{WuPVYzPCEQvF2= MYHTRW5ITVJ?
TUR Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETIXG9KSzVyPUO2MlA2OjFizszN MWXTRW5ITVJ?
REH M4HGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLRVJRGUUN3ME2zO{45OjFzIN88US=> NVzqS3FLW0GQR1XS
EW-22 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR{LkK4PFUh|ryP M{TPS3NCVkeHUh?=
NCI-H446 NX3xbYFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvRbFVKSzVyPUSyMlc5PTNizszN NWf3N4NqW0GQR1XS
ES3 M3HqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR|LkGzN|kh|ryP NVnmXZZsW0GQR1XS
EW-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVf5dVBlUUN3ME20OE45OjF6IN88US=> M4TyZ3NCVkeHUh?=
RH-1 NGTVbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzPTWM2OD12Nz61PFEzKM7:TR?= NYPSTVc6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • Answer:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID